Levobupivacaine Market

The Levobupivacaine market was valued at USD840.4 Mn by 2019. Constantly increasing surgical procedures and labor pain experienced during live births primarily determines levobupivacaine market growth. Furthermore, a significant rise in the number of fatal and traumatic accidents inflicting grievous injuries and rising demand for post-operative pain management further accentuates its market growth.

Levobupivacaine is classified as a local anesthetic drug and is the S-enantiomer of bupivacaine drug. It belongs to the amino amide group and has gained immense popularity among anesthesiologists as a local anesthetic drug owing to its less cardiotoxicity and motor blockade. It is a long-acting anesthetic drug that was developed due to a significant increase in the reported incidents of cardiac arrest and seizures associated with the use of intravascular injection of bupivacaine. The excellent pharmacokinetic properties such as the volume of distribution and rate of clearance render it safe and efficacious in comparison to other anesthetic agents such as ropivacaine and bupivacaine.

The major segments related to the levobupivacaine market are:

By Clinical Application (2017–2027; US$ Mn)

Epidural Anesthesia

Spinal Anesthesia

Peripheral Nerve Blocks

Others

By End User (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global levobupivacaine market
• The overall segmentation of the levobupivacaine market, by clinical application, end-user, and geography is minutely studied. Epidural anesthesia and hospital pharmacy are dominating the clinical application and end-user segments respectively
• Significant rise in the number of surgical procedures worldwide and increasing demand for post-operative pain management together drives the levobupivacaine market
• Excellent drug profile exhibited by levobupivacaine makes it more safe and efficacious in comparison to other local anesthetic drugs

Report gist?

• The study of the global levobupivacaine market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and end-user and categorization of the same at geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

• This study is suitable for industry participants and stakeholders in the medical device manufacturers engaged in manufacturing and marketing of levobupivacaine which is gaining huge demand owing to a significant rise in surgical procedures worldwide and increasing demand for postoperative pain management
• The report will benefit anesthesiologist engaged in performing painless surgical procedures
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to levobupivacaine market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Epidural anesthesia is holding the largest market share in the clinical application segment for levobupivacaine market. It is considered as the most common type of anesthesia which is used for achieving pain relief during labor. A significant rise in the number of live births worldwide and its capability to increase or decrease the dose of local anesthetic agents according to the pain crescendo experienced by the patient increases its popularity among anesthesiologists worldwide. Peripheral nerve blocks are basically utilized to numb the nerves of the body part subjected to surgical procedures and the anesthetic effect remains post-surgery to provide comfort to the ailing patient. It is anticipated to witness rapid market growth during the forecast period owing to the significant rise in traumatic accidents requiring immediate surgical procedures to treat grievous injuries.

Hospital pharmacy is reigning the end-user segment for the levobupivacaine market. The inherent features such as accurate and precise dosing of anesthetic agents used in surgical procedures and capability to serve the medical needs of patients 24/7 primarily determines its market dominance. Retail pharmacy is growing at a significant pace in the developing regions on account of the presence of a huge generic market for local anesthetics and the provision of medicines at a discounted rate determines its market growth for levobupivacaine.

North America is holding the largest market share in the geography segment for levobupivacaine market. The major factors responsible for its market dominance are the significant rise in the number of surgical procedures performed and the effective implementation of guidelines pertaining to pain management. Furthermore the affordable reimbursement scenario pertaining to the use of levobupivacaine in surgical procedures accentuates the market growth in the region. Europe is representing the second largest regional market on account of a significant rise in the number of dental and cosmetic surgeries and the growing trend of use of long-acting anesthetic agents in post-operative pain management. Asia Pacific is keen to register rampant market growth during the forecast period owing to the constant growth in the medical tourism industry and developing healthcare infrastructure.